Drug development for sickle-cell disease, largely neglected for decades, is becoming a crowded field: two papers published on Saturday in the New England Journal of Medicine give promising results from a study of experimental therapies, including Crisper gene editing for the disease. In addition, Beam Therapeutics Inc. The American Society …
Read More »Gene editing shows promise in sickle-cell disease
